Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: J Am Coll Surg. 2020 Dec 13;232(4):361–371. doi: 10.1016/j.jamcollsurg.2020.11.017

Figure 2.

Figure 2.

(A) In patients with tumor burden within Milan criteria, the overall survival rate for combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) was comparable to the overall survival rate for HCC (p=0.806). (B) Similarly, there was no significant difference in disease-free survival (p=0.740). (C) The recurrence rate was significantly higher for cHCC-CCA within Milan criteria compared to HCC within Milan Criteria lower (p<.001).